☒ Annual Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act Of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (Exact name of registrant as specified in its charter) | Delaware | 74-2963609 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | 100 Park Ave., 23 Floor For the fiscal year ended December 31, 2024 New York, NY 10017 or ☐ Transition Report Pursuant To Sec ...

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Actinium Pharmaceuticals, Inc. (ATNM) Misled Investors Regarding FDA Approval of Iomab-B SAN DIEGO, March 28, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (NYSE: ATNM) securities between October 31 ...

Core Viewpoint - A securities class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for allegedly making false and misleading statements regarding its business and the approval process for its Iomab-B BLA [1][2]. Group 1: Allegations and Claims - The lawsuit claims that the defendants failed to disclose that data from the Sierra Trial was unlikely to meet FDA guidelines for the Iomab-B BLA approval [2]. - It is alleged that additional analyses provided to the FDA to support the Sierra Trial's data were also unlikely to satisfy the FDA's requirements [2]. - The complaint suggests that the FDA would likely refuse to review the Iomab-B BLA or that the application would not be approved in its current form [2]. - Defendants' positive statements regarding the company's business and prospects are claimed to be materially misleading [2]. Group 2: Market Reaction - The truth about the inadequacy of the Sierra Trial data began to emerge on August 5, 2024, leading to a significant decline in Actinium's stock price, which harmed investors [3]. Group 3: Investor Information - Investors who acquired shares of Actinium are encouraged to contact the law firm before the lead plaintiff motion deadline on May 26, 2025, to discuss their rights [4].

ATLANTA, March 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). The lawsuit alleges that Defendants made materially false and/or misleading statements, and/or failed to disclose material adverse facts, including allegations that: (i) Actinium “repeatedly touted the Sierra Trial’s positive DCR data while downplaying the study’s failure to generate statistically significant or clinically meaningful ...

-  99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models -  ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model - Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant prostate cancer models NEW YORK, March 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the develo ...

PALM BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Industry experts see the global radiotherapy market continuing to grow in the years to come. A recent report from MarketsAndMarkets said that the global radiotherapy market, which was valued at US$6.23 billion in 2022, grew at a robust CAGR of 4.9%, and reached US$7.21 billion in 2024 and is expected to reach an impressive US$9.62 billion by 2030. It said: "During the forecast years, the growth of the market is attributed ...

- ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting - Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding clinical trials and to leverage its proprietary Actinium-225 cyclotron manufacturing technology - Data from several clinical trials expected in 2H:2025 across myeloid malignancies, solid tumors and cell and gene therapy conditi ...

- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure - Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy conditioning with clinical data expected in 2025 supporting each addressable market - Presentation follows Investor KOL Event and Company Update on March 25th NEW YORK, March 2 ...

Core Insights - Actinium Pharmaceuticals is presenting three multi-billion-dollar market opportunities for its products Actimab-A and Iomab-ACT in the treatment of myeloid malignancies, solid tumors, and cell & gene therapy conditioning [1][2] Group 1: Actimab-A Developments - Actimab-A is being positioned as a mutation-agnostic backbone therapy for myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) across various treatment settings [2][3] - Clinical results for Actimab-A show high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity in relapsed/refractory AML patients, leading to improved survival outcomes [3][4] - A pivotal Phase 2/3 clinical trial for Actimab-A in relapsed/refractory AML is planned, along with trials under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) [1][3] Group 2: Solid Tumor Program - Actinium is advancing a solid tumor program for Actimab-A, which includes head-to-head clinical trials evaluating its combination with PD-1 inhibitors like KEYTRUDA and OPDIVO against these inhibitors alone [1][3] - The trials will initially focus on patients with head and neck squamous cell carcinoma and non-small cell lung cancer [1] Group 3: Iomab-ACT and Future Prospects - Iomab-ACT is being developed as a universal targeted conditioning agent to enhance patient access to cell and gene therapies and improve outcomes [2][3] - Actinium is also seeking a strategic partner for Iomab-B, which serves as an induction and conditioning agent prior to bone marrow transplant in patients with relapsed/refractory AML [4]

NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidate ...